{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:02:30Z","timestamp":1753876950975,"version":"3.41.2"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Background: The closure of a pharmacy-led anticoagulation clinic, which provided point-of-care (POC) international normalized ratio (INR) testing and face-to-face visits, coupled with the transition to an academic physician-led clinic without POC INR testing and reliance on telephone communication, created significant challenges for warfarin management during the Coronavirus disease 2019 pandemic. The aim of this quality control project was to increase the percentage of patients on warfarin within the optimal time in therapeutic range (TTR) from 52.30% to 65.00%, sustain baseline quarterly cumulative percentage TTR to 59.00%, and transition 20% of eligible patients from warfarin to dual oral anticoagulation (DOAC) within 12\u2009months.<\/jats:p>\n               <jats:p>Methods: A multidisciplinary team employed a Fishbone diagram, stakeholder analysis, process flow map, and a driver diagram. Significant barriers included knowledge gaps, fear of blood draws, lack of POC INR testing, and noninteroperable electronic health records (EHRs). Primary outcome measures included quarterly cumulative percentage TTR, 2-monthly percentage TTR, and the percentage of eligible patients switched to DOAC. Process measures included INR completion rates. Key interventions involved educating patients and the care team, transitioning patients to DOAC, improving EHRs, and optimizing processes. Data analysis utilized run charts.<\/jats:p>\n               <jats:p>Results: Monthly INR completion rates rose from 63% to 87% within 12\u2009months and reached 92% during the 6\u2009months post-project period. Among 143 patients, 40.55% (58) were eligible for a DOAC switch, with 51.72% (30\/58) successfully transitioning during the project and the 6-month post-project period. Two-monthly TTR rates improved from the baseline of 52.30% to 62.00% during the study period and remained sustainable at 62.80% in the post-project phase. Quarterly cumulative TTR rates remained stable at 59.20% during the study period in 2021. The quarterly cumulative TTR rates continued to increase at 60.50% and 64.40% in 2022 and 2023, respectively, during the post-project period. No bleeding episodes occurred during the 15-month post-project period.<\/jats:p>\n               <jats:p>Conclusion: Multi-faceted strategies significantly improved warfarin safety during the project and maintained these improvements for 24\u2009months. Transitioning from warfarin to DOACs was crucial for optimizing anticoagulation management with limited resources. The lead physician and team used various tools to address barriers to effective warfarin management, ensure appropriate DOAC prescribing, and enhance practices for DOAC prescriptions. This project effectively addressed barriers, improved population health, and provided a model for anticoagulation management in primary care settings.<\/jats:p>","DOI":"10.1093\/intqhc\/mzae092","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T07:49:27Z","timestamp":1726818567000},"source":"Crossref","is-referenced-by-count":0,"title":["Optimizing warfarin and dual oral anticoagulation practices in an academic clinic during a merger amid the COVID-19 pandemic in a marginalized population"],"prefix":"10.1093","volume":"36","author":[{"given":"Ronak","family":"Bahuva","sequence":"first","affiliation":[{"name":"University at Buffalo, The State University of New York , Buffalo, NY,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacquelyn","family":"Jordan","sequence":"additional","affiliation":[{"name":"University at Buffalo, The State University of New York , Buffalo, NY,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yadunath","family":"Pokharel","sequence":"additional","affiliation":[{"name":"University at Buffalo, The State University of New York , Buffalo, NY,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica L","family":"Reynolds","sequence":"additional","affiliation":[{"name":"University at Buffalo, The State University of New York , Buffalo, NY,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9212-4478","authenticated-orcid":false,"given":"Smita","family":"Bakhai","sequence":"additional","affiliation":[{"name":"University at Buffalo, The State University of New York , Buffalo, NY,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,9,20]]},"reference":[{"key":"2024100315112258200_R1","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.thromres.2020.11.004","article-title":"Switching warfarin patients to a direct oral anticoagulant during the coronavirus disease-19 pandemic","volume":"197","author":"Patel","year":"2021","journal-title":"Thromb Res"},{"key":"2024100315112258200_R2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/rth2.12157","article-title":"Barriers to integrating direct oral anticoagulants into anticoagulation clinic care: a mixed-methods study","volume":"3","author":"Barnes","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"2024100315112258200_R3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s11239-020-02138-z","article-title":"Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum","volume":"50","author":"Barnes","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"2024100315112258200_R4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/1060028014555176","article-title":"Features of electronic health records necessary for the delivery of optimized anticoagulant therapy: consensus of the EHR task force of the New York State Anticoagulation Coalition","volume":"49","author":"Spyropoulos","year":"2015","journal-title":"Ann Pharmacother"},{"key":"2024100315112258200_R5","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.jcjq.2018.04.015","article-title":"Defining minimum necessary anticoagulation-related communication at discharge: consensus of the care transitions task force of the New York state anticoagulation coalition","volume":"44","author":"Triller","year":"2018","journal-title":"Jt Comm J Qual Patient Saf"},{"key":"2024100315112258200_R6","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1182\/bloodadvances.2018024893","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy","volume":"2","author":"Witt","year":"2018","journal-title":"Blood Adv"},{"key":"2024100315112258200_R7","doi-asserted-by":"publisher","first-page":"e419S","DOI":"10.1378\/chest.11-2301","article-title":"Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Kearon","year":"2012","journal-title":"Chest"},{"key":"2024100315112258200_R8","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"2024100315112258200_R9","article-title":"Evaluation of warfarin patients with low time in therapeutic range (TTR) for transition to non-vitamin-K oral anticoagulant (NOAC) therapy","volume":"44","author":"Fovel","year":"2019","journal-title":"Pharm Ther"},{"key":"2024100315112258200_R10","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","article-title":"Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report","volume":"154","author":"Lip","year":"2018","journal-title":"Chest"},{"key":"2024100315112258200_R11","first-page":"548","article-title":"Implementation of quality assurance and medical audit: general practitioners\u2019 perceived obstacles and requirements","volume":"45","author":"Grol","year":"1995","journal-title":"Br J Gen Pract"},{"article-title":"Content last reviewed December 2022","volume-title":"Agency for Healthcare Research and Quality","author":"Six Domains of Healthcare Quality","key":"2024100315112258200_R12"},{"article-title":"Stakeholder mapping","year":"1991","author":"Mendelow","key":"2024100315112258200_R13"},{"key":"2024100315112258200_R14","doi-asserted-by":"publisher","first-page":"771","DOI":"10.4300\/jgme-d-16-00558.1","article-title":"The SQUIRE guidelines: a scholarly approach to quality improvement","volume":"8","author":"McQuillan","year":"2016","journal-title":"J Grad Med Educ"},{"author":"INRPRO","key":"2024100315112258200_R15","article-title":"Rosendaal Method for % INR in range"},{"key":"2024100315112258200_R16","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct oral anticoagulant use: a practical guide to common clinical challenges","volume":"9","author":"Chen","year":"2020","journal-title":"J Am Heart Assoc"},{"author":"Agency for Healthcare Research and Quality","key":"2024100315112258200_R17","article-title":"Content last reviewed September 2020"},{"key":"2024100315112258200_R18","doi-asserted-by":"publisher","first-page":"688","DOI":"10.7326\/m19-3495","article-title":"Annals clinical decision making: communicating risk and engaging patients in shared decision making","volume":"172","author":"Armstrong","year":"2020","journal-title":"Ann Intern Med"},{"key":"2024100315112258200_R19","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1136\/bmjqs-2022-015221","article-title":"Measuring what matters: refining our approach to quality indicators","volume":"32","author":"Marang-van de Mheen","year":"2023","journal-title":"BMJ Qual Saf"},{"volume-title":"Advancing Anticoagulation Stewardship: A Playbook","year":"2022","author":"National Quality Forum (NQF)","key":"2024100315112258200_R20"},{"key":"2024100315112258200_R21","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jcjq.2021.10.007","article-title":"Building a targeted automatic e-consult (TACo) program","volume":"48","author":"Judson","year":"2022","journal-title":"Jt Comm J Qual Patient Saf"},{"key":"2024100315112258200_R22","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1182\/asheducation-2018.1.348","article-title":"Role of the anticoagulant monitoring service in 2018: beyond warfarin","volume":"2018","author":"Clark","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2024100315112258200_R23","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1007\/s11096-019-00844-0","article-title":"Creating an interprofessional guideline to support patients receiving oral anticoagulation therapy: a Delphi exercise","volume":"41","author":"Damen","year":"2019","journal-title":"Int J Clin Pharm"},{"key":"2024100315112258200_R24","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1370\/afm.739","article-title":"Improving anticoagulation therapy using point-of-care testing and a standardized protocol","volume":"6","author":"Franke","year":"2008","journal-title":"Ann Fam Med"},{"key":"2024100315112258200_R25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2024.102427","article-title":"Evaluation of warfarin management in primary health care centers in Qatar: a retrospective cross-sectional analysis of the national dataset","volume":"49","author":"Alshihab","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"2024100315112258200_R26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjoq-2022-002216","article-title":"Direct oral anticoagulant (DOAC) monitoring within primary care: a quality improvement project","volume":"12","author":"McFadzean","year":"2023","journal-title":"BMJ Open Qual"},{"key":"2024100315112258200_R27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-151830","article-title":"Transitioning eligible patients from warfarin to a direct oral anticoagulant: a prospective quality improvement study","volume":"137","author":"Wang","year":"2021","journal-title":"Blood"},{"key":"2024100315112258200_R28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjhci-2022-100683","article-title":"Clinical decision support systems to improve drug prescription and therapy optimisation in clinical practice: a scoping review","volume":"30","author":"Armando","year":"2023","journal-title":"BMJ Health Care Inform"}],"container-title":["International Journal for Quality in Health Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/intqhc\/advance-article-pdf\/doi\/10.1093\/intqhc\/mzae092\/59207174\/mzae092.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/intqhc\/article-pdf\/36\/3\/mzae092\/59555941\/mzae092.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/intqhc\/article-pdf\/36\/3\/mzae092\/59555941\/mzae092.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T15:11:33Z","timestamp":1727968293000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/intqhc\/article\/doi\/10.1093\/intqhc\/mzae092\/7762301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,20]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/intqhc\/mzae092","relation":{},"ISSN":["1353-4505","1464-3677"],"issn-type":[{"type":"print","value":"1353-4505"},{"type":"electronic","value":"1464-3677"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,9,20]]},"article-number":"mzae092"}}